Clinical Trial

Biomarker Guided Treatment in Gynaecological Cancer

Study acronym: Momatec2
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 28, 2017 (before its estimated December 2020 completion). Its status may not reflect the trial's current state.
Summary
MoMaTEC2 aims to test, in clinically oriented studies, the applicability of already identified and promising molecular biomarkers, to promote individualisation of treatment for patients with endometrial cancer. Predominantly, but not exclusively, such biomarkers have shown to be interesting in retrospective analysis of our large prospectively collected MoMaTEC1 series. Part 1: Performance of a phase 4 implementation trial for optimised stratification of surgical treatment, specifically the performance of (para-aortic and pelvic) lymphadenectomy guided by validated biomarkers. Part 2: Performance of a phase 2b clinical biomarker study to evaluate the predictive potential of the biomarker stathmin for taxane treatment response in endometrial and ovarian cancer. In this study stathmin will be used as integrated biomarker.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2015-09-04; most recent amendment 2017-03-24.
Status change: Not Yet Recruiting → Recruiting 2016-01-13
Trial Details
NCT Number NCT02543710
Lead Sponsor Haukeland University Hospital
Conditions Endometrial Cancer
Enrollment 1,300 participants
Start Date 2015-10
Primary Completion 2020-12 (estimated)
Study Completion 2033-12 (estimated)
Updated on ClinicalTrials.gov 2017-03-28